![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan (M.H., K.M., Y.Su.); and School of Pharmaceutical Sciences, Showa University, Tokyo, Japan (Y.Sh.)
Pitavastatin, a novel potent 3-hydroxymethylglutaryl-CoA reductase inhibitor, is selectively distributed to the liver in rats. However, the hepatic uptake mechanism of pitavastatin has not been clarified yet. In the present study, we investigated the contribution of organic anion transporting polypeptide 2 (OATP2/OATP1B1) and OATP8 (OATP1B3) to pitavastatin uptake using transporter-expressing HEK293 cells and human cryopreserved hepatocytes. Uptake studies using OATP2- and OATP8-expressing cells revealed a saturable and Na+-independent uptake, with Km values of 3.0 and 3.3 µM for OATP2 and OATP8, respectively. To determine which transporter is more important for its hepatic uptake, we proposed a methodology for estimating their quantitative contribution to the overall hepatic uptake by comparing the uptake clearance of pitavastatin with that of reference compounds (a selective substrate for OATP2 (estrone-3-sulfate) and OATP8 (cholecystokinin octapeptide) in expression systems and human hepatocytes. The concept of this method is similar to the so-called relative activity factor method often used in estimating the contribution of each cytochrome P450 isoform to the overall metabolism. Applying this method to pitavastatin, the observed uptake clearance in human hepatocytes could be almost completely accounted for by OATP2 and OATP8, and about 90% of the total hepatic clearance could be accounted for by OATP2. This result was also supported by estimating the relative expression level of each transporter in expression systems and hepatocytes by Western blot analysis. These results suggest that OATP2 is the most important transporter for the hepatic uptake of pitavastatin in humans.
Address correspondence to: Dr. Yuichi Sugiyama, Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp
This article has been cited by other articles:
|
|
 |
|
  A. Poirier, T. Lave, R. Portmann, M.-E. Brun, F. Senner, M. Kansy, H.-P. Grimm, and C. Funk Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model Drug Metab. Dispos., December 1, 2008; 36(12): 2434 - 2444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kitamura, K. Maeda, Y. Wang, and Y. Sugiyama Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin Drug Metab. Dispos., October 1, 2008; 36(10): 2014 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Abe, A. S. Bridges, W. Yue, and K. L. R. Brouwer In Vitro Biliary Clearance of Angiotensin II Receptor Blockers and 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors in Sandwich-Cultured Rat Hepatocytes: Comparison with in Vivo Biliary Clearance J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 983 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sakamoto, H. Kusuhara, K. Horie, K. Takahashi, T. Baba, J. Ishizaki, and Y. Sugiyama Identification of the Transporters Involved in the Hepatobiliary Transport and Intestinal Efflux of Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) Glucuronide, a Pharmacologically Active Metabolite of S-8921 Drug Metab. Dispos., August 1, 2008; 36(8): 1553 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Grime, P. J. H. Webborn, and R. J. Riley Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes Drug Metab. Dispos., August 1, 2008; 36(8): 1670 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsushima, K. Maeda, N. Ishiguro, T. Igarashi, and Y. Sugiyama Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans Drug Metab. Dispos., April 1, 2008; 36(4): 663 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ishiguro, K. Maeda, A. Saito, W. Kishimoto, S. Matsushima, T. Ebner, W. Roth, T. Igarashi, and Y. Sugiyama Establishment of a Set of Double Transfectants Coexpressing Organic Anion Transporting Polypeptide 1B3 and Hepatic Efflux Transporters for the Characterization of the Hepatobiliary Transport of Telmisartan Acylglucuronide Drug Metab. Dispos., April 1, 2008; 36(4): 796 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kalliokoski, M. Neuvonen, P. J. Neuvonen, and M. Niemi Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide J. Clin. Pharmacol., March 1, 2008; 48(3): 311 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. J. Bow, J. L. Perry, D. S. Miller, J. B. Pritchard, and K. L. R. Brouwer Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in Freshly Isolated Rat Hepatocytes Drug Metab. Dispos., January 1, 2008; 36(1): 198 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yamada, K. Maeda, E. Kamiyama, D. Sugiyama, T. Kondo, Y. Shiroyanagi, H. Nakazawa, T. Okano, M. Adachi, J. D. Schuetz, et al. Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor Drug Metab. Dispos., December 1, 2007; 35(12): 2166 - 2176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Noe, R. Portmann, M.-E. Brun, and C. Funk Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3 Drug Metab. Dispos., August 1, 2007; 35(8): 1308 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hallifax and J. B. Houston Saturable Uptake of Lipophilic Amine Drugs into Isolated Hepatocytes: Mechanisms and Consequences for Quantitative Clearance Prediction Drug Metab. Dispos., August 1, 2007; 35(8): 1325 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Soars, K. Grime, J. L. Sproston, P. J. H. Webborn, and R. J. Riley Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo Drug Metab. Dispos., June 1, 2007; 35(6): 859 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nozaki, H. Kusuhara, T. Kondo, M. Hasegawa, Y. Shiroyanagi, H. Nakazawa, T. Okano, and Y. Sugiyama Characterization of the Uptake of Organic Anion Transporter (OAT) 1 and OAT3 Substrates by Human Kidney Slices J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 362 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hirano, K. Maeda, Y. Shitara, and Y. Sugiyama DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 Drug Metab. Dispos., July 1, 2006; 34(7): 1229 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ishiguro, K. Maeda, W. Kishimoto, A. Saito, A. Harada, T. Ebner, W. Roth, T. Igarashi, and Y. Sugiyama PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS Drug Metab. Dispos., July 1, 2006; 34(7): 1109 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yamashiro, K. Maeda, M. Hirouchi, Y. Adachi, Z. Hu, and Y. Sugiyama INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS Drug Metab. Dispos., July 1, 2006; 34(7): 1247 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Huang, Y. Wang, and S. Grimm ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN Drug Metab. Dispos., May 1, 2006; 34(5): 738 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, K. Johnson, J. Paulauskis, and J. Cook So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J. Clin. Pharmacol., March 1, 2006; 46(3): 258 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shimizu, K. Fuse, K. Okudaira, R. Nishigaki, K. Maeda, H. Kusuhara, and Y. Sugiyama CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS Drug Metab. Dispos., October 1, 2005; 33(10): 1477 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsushima, K. Maeda, C. Kondo, M. Hirano, M. Sasaki, H. Suzuki, and Y. Sugiyama Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer Resistance Protein J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1059 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hirano, K. Maeda, S. Matsushima, Y. Nozaki, H. Kusuhara, and Y. Sugiyama Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin Mol. Pharmacol., September 1, 2005; 68(3): 800 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Morita, H. Kusuhara, Y. Nozaki, H. Endou, and Y. Sugiyama FUNCTIONAL INVOLVEMENT OF RAT ORGANIC ANION TRANSPORTER 2 (SLC22A7) IN THE HEPATIC UPTAKE OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG KETOPROFEN Drug Metab. Dispos., August 1, 2005; 33(8): 1151 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chang, K. S. Pang, P. W. Swaan, and S. Ekins Comparative Pharmacophore Modeling of Organic Anion Transporting Polypeptides: A Meta-Analysis of Rat Oatp1a1 and Human OATP1B1 J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 533 - 541. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
